On this page

Direct-to-patient partner reporting is how a telehealth or pharmacy partner shows a drugmaker's program what happened after the handoff: how many visitors from each campaign became consults, prescriptions and paid fills, and how many refilled, reported in aggregate with no patient names or contact details. In Curve Compliance's method, a partner connects once, sends a stripped-down event at each step carrying the campaign that brought the patient, and sees its own results.

Book a call. Are you a telehealth or pharmacy partner in a drugmaker's direct-to-patient program? Curve's team can show how step events, aggregate results by channel, campaign and partner, and your own results view fit together. Book a call with Curve.

Why do drugmakers lose sight of patients at the partner handoff?

More manufacturers now sell through partners. L.E.K. Consulting wrote in 2026 that “Biopharma leaders are increasingly treating DTC as a durable commercialization component rather than a tactical add-on,” and its Figure 1 lists 11 manufacturer platforms, with workflow columns for a telehealth HCP finder, cash, insurance pay and partner pharmacy delivery (L.E.K. Consulting, 2026). In March 2026, Managed Healthcare Executive reported that for a new cash-pay subscription program, “Novo Nordisk is offering the subscriptions through telehealth providers” (Managed Healthcare Executive).

Once the patient leaves the brand site, the drugmaker's view usually ends. Cash purchases may not show up in insurance data either: HealthVerity notes that patients in direct-to-consumer programs “can disappear from closed payer claims data even though treatment has not stopped” (HealthVerity). The partner holds the record of what happened next. Partner reporting turns that record into numbers the program can use, without moving patient identities.

The industry is still writing the rules for this. The Digital Medicine Society's initiative, launched in April 2026 with leading pharma organizations, will “define how to measure patient access and affordability” (DiMe release), and its CEO wrote that the pathway “is expanding far faster than the oversight, standards, and evidence needed to keep pace” (pharmaphorum). A partner that can show clean, consistent numbers today is easier to work with while those standards form.

What should a partner report to a drugmaker program?

The steps a patient takes after the handoff, each as a small event with the step, the time and the campaign that brought the patient, and nothing that names the patient. The program sees those events only as totals.

StepWhat the partner sendsWhat the program sees
VisitAn event when a visitor from the brand site starts intake, with the campaign attachedVisits by channel, campaign and partner
ConsultAn event when the consult is completedConsult rate by campaign and partner
PrescriptionAn event when a prescription is writtenPrescriptions by campaign and partner
Paid fillAn event when the first fill is paidPaid fills and cost per paid fill by campaign
Refill at month 3An event at each refillShare of patients refilling at month 3, by partner
Refill at month 6An event at each refillShare of patients refilling at month 6, by partner

Agree the definitions before the first event is sent. If one partner counts a consult when it is booked and another when it is completed, the partner columns stop being comparable, and a strong partner can look weak. The same goes for a paid fill: decide whether it means the first paid order, the first shipped order or the first order that was not refunded, and keep that definition for every partner in the program.

How can a partner report results without sharing patient identities?

Design for aggregates from the start. In this method, each event carries the step and the campaign with no name or contact details, and the drugmaker receives aggregate results by channel, campaign and partner. That answers the program's questions (which campaigns produce paid fills, and what each paid fill costs) without a patient list changing hands.

Three practices make aggregates safer still, and both sides should agree them in writing: a minimum group size below which counts are suppressed or combined, reporting windows of weeks or months rather than exact dates, and contract terms that bar anyone who receives a report from re-identifying patients. A partner that is a HIPAA covered entity or business associate also has its own obligations for anything it shares, so talk to your counsel before you sign a data-sharing agreement with a manufacturer. If you are not sure HIPAA applies to your cash-pay service at all, start with does HIPAA apply to cash-pay telehealth.

How does the ad click follow a patient from the brand site to the partner?

The drugmaker's ad brings a visitor to the brand site, and the brand site sends them on to a partner's intake, usually on another domain. If the click is lost at that step, every later event arrives without a campaign, and the program can't tell which campaign produced the patient. Curve keeps the ad click attached when a visitor leaves a site for a booking or intake step on another system, and outcomes recorded days later still match. Common booking tools are built in, and other systems are connected through setup by Curve's team.

How does a partner send step events?

Through one connection. Curve receives outcomes from other systems through incoming webhooks and offline conversion uploads from a CRM or EHR, and credits each to the original ad click. In this method, a partner's intake, prescribing or pharmacy system posts a consult, prescription or paid fill event to an incoming webhook, or the partner uploads a file of events. Those step events feed the program's aggregate reporting.

Partners connect once and see their own results, and the partner tools are open to every partner in the program. That matters to the partner: seeing your own results lets you spot and fix a weak step in your intake early.

Why does retention belong in partner reporting?

Because a first fill is only the start. IQVIA's February 2026 post cites a recent analysis of 180-day adherence data for two GLP-1 brands: patients using direct-to-patient vial channels “maintain adherence levels comparable to those with commercial insurance,” while the cash card cohorts in that data “lag behind slightly” (IQVIA, February 10, 2026). IQVIA also warns that for patients paying out of pocket, “without robust support, persistence declines quickly.” The support a partner gives after the first fill is part of what it brings to a program, and refills are how it shows.

In this method, refills at month 3 and month 6 can be reported by partner, in aggregate. Compare like with like: the same product, the same form and the same start window, because cohorts that started in different months or channels are not directly comparable. For the clinic-side view of keeping patients on a program, see how clinics reduce GLP-1 program drop-off.

How Curve Compliance helps

For your own advertising, Curve replaces browser ad pixels with one script and sends conversions server-side to Meta Conversions API, Google Ads, TikTok, Microsoft Advertising and LinkedIn. Each platform receives only a fixed list of fields, contact identifiers are off by default and SHA-256 hashed when enabled, and events can use neutral names. Curve strips PHI before data reaches an ad platform and flags PHI-like patterns so they can be stopped at the source, and Event Logs show what Curve sent to each platform and what the platform accepted. See Curve for telehealth, Curve for online pharmacies and HIPAA-compliant conversion tracking for telehealth.

In this method, Curve keeps the ad click attached when a visitor moves from a drugmaker's brand site to your intake, and receives your step events through an incoming webhook or a file upload, crediting each to the original ad click. You connect once and see your own results, and the partner tools are open to every partner in the program. The drugmaker's team receives aggregate results by channel, campaign and partner, including cost per paid fill, and refills at month 3 and month 6 can be reported by partner, in aggregate.

Curve signs a BAA on every plan, holds SOC 2 Type II, and its team does the setup, typically live in about a week, case by case. Book a call to see how partner reporting would work with your intake and pharmacy systems.

For the drugmaker side of the same reports, see direct-to-patient pharma attribution.

These are the telehealth partner metrics a drugmaker reads, in aggregate.

Sources, checked November 20, 2026: L.E.K. Consulting, 2026; Managed Healthcare Executive, March 31, 2026; HealthVerity, January 14, 2026; IQVIA, February 10, 2026; DiMe release, April 16, 2026; pharmaphorum, December 2, 2025.

Frequently Asked Questions

What is direct-to-patient partner reporting?

It is a telehealth or pharmacy partner's report to a drugmaker's direct-to-patient program of what happened after the handoff: consults, prescriptions, paid fills and refills by campaign. It is shared in aggregate, with no patient names or contact details.

Does the drugmaker see patient names?

The drugmaker receives aggregate results by channel, campaign and partner. In this method each event carries the step and the campaign, and names and contact details stay with the partner.

Can a partner see its own results?

Yes. Partners connect once and see their own results, and the partner tools are open to every partner in the program.

How do step events reach Curve?

Through an incoming webhook or an offline conversion upload from a CRM or EHR. Curve credits each event to the original ad click, and Curve's team does the setup.

Does partner reporting steer patients toward one partner?

It shouldn't. Reports describe what happened after a patient chose a partner, and in this method the partner tools are open to every partner in the program.

How are refills reported?

Refills at month 3 and month 6 can be reported by partner, in aggregate. Compare cohorts that started in the same window on the same product and form.

Does Curve Compliance sign a BAA?

Yes. Curve signs a BAA on every plan and holds SOC 2 Type II.

Talk to Curve Compliance

Book a call. Want to show a drugmaker's program what happens after the handoff, without sharing patient identities? Curve's team does the setup, typically live in about a week, case by case. Book a call with Curve.